{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T09:58:19Z","timestamp":1781517499129,"version":"3.54.1"},"reference-count":37,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T00:00:00Z","timestamp":1700179200000},"content-version":"unspecified","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001858","name":"VINNOVA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007949","name":"Reumatikerf\u00f6rbundet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007949","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011727","name":"Stockholm l\u00e4ns landsting","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011727","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003793","name":"Hj\u00e4rt-Lungfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003793","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2023,10,9]]},"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To assess associations between inflammatory remission, formal treatment targets and the likelihood of starting a new disease-modifying antirheumatic drug (DMARD), among patients with early rheumatoid arthritis (RA).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients newly diagnosed with RA were identified in the Swedish Rheumatology Quality Register (n=11\u2009784). Disease Activity Score 28 (DAS28) and DMARD-treatment were assessed at RA diagnosis and 3, 6, 12 and 24 months thereafter. Inflammatory remission was defined as: swollen joints (0\u201328)=0\u2009and C reactive protein &lt;10\u2009mg\/L and normal erythrocyte sedimentation rate. The primary treatment target was DAS28 remission (&lt;2.6). The proportion of patients in inflammatory remission who failed to reach DAS28 targets was assessed at each follow-up visit, and their likelihood of starting a new DMARD was compared with patients in inflammatory remission who reached the treatment target. rate ratios (RR) and 95% CIs were estimated with modified Poisson regression.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Overall, 34%, 39%, 44% and 47% were in inflammatory remission at 3, 6, 12 and 24 months. Among these, 20%, 22%, 20% and 19%, respectively, failed to reach DAS28 remission. Patients who failed to reach DAS28 remission despite being in inflammatory remission were more likely to start a new DMARD treatment (RR (95%\u2009CI) at 6 months=1.59 (1.29 to 1.96), 12 months=1.52 (1.23 to 1.87)) and 24 months=1.47 (1.20 to 1.80).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Failing to reach formal treatment targets, despite being in inflammatory remission, is common among patients with early RA, and is associated with an increased likelihood of starting a new DMARD-treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2023-003111","type":"journal-article","created":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T22:50:28Z","timestamp":1700175028000},"page":"e003111","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Register-based observational study of associations between inflammatory remission, formal treatment targets and the use of disease-modifying antirheumatic drugs among patients with early rheumatoid arthritis"],"prefix":"10.1136","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8676-3521","authenticated-orcid":false,"given":"Joakim","family":"Lindqvist","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden"},{"name":"Medical Unit of Gastroenterology, Dermatology and Rheumatology, Theme Inflammation and Ageing, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0433-0616","authenticated-orcid":false,"given":"Johan","family":"Askling","sequence":"additional","affiliation":[{"name":"Medical Unit of Gastroenterology, Dermatology and Rheumatology, Theme Inflammation and Ageing, Karolinska University Hospital, Stockholm, Sweden"},{"name":"Clinical Epidemiology Division, Department of Medicine, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Lampa","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden"},{"name":"Medical Unit of Gastroenterology, Dermatology and Rheumatology, Theme Inflammation and Ageing, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,11,16]]},"reference":[{"key":"2025090313044147000_9.4.e003111.1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207524"},{"key":"2025090313044147000_9.4.e003111.2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.100271"},{"key":"2025090313044147000_9.4.e003111.3","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/acr.20151","article-title":"Patient perspective of measuring treatment efficacy: the rheumatoid arthritis patient priorities for pharmacologic interventions outcomes","volume":"62","author":"Sanderson","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090313044147000_9.4.e003111.4","first-page":"94","article-title":"Pain mechanisms in rheumatoid arthritis","volume":"35 Suppl 107","author":"McWilliams","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"2025090313044147000_9.4.e003111.5","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep458"},{"key":"2025090313044147000_9.4.e003111.6","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1080\/03009742.2020.1846778","article-title":"Widespread non-joint pain in early rheumatoid arthritis","volume":"50","author":"Schelin","year":"2021","journal-title":"Scand J Rheumatol"},{"key":"2025090313044147000_9.4.e003111.7","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130493"},{"key":"2025090313044147000_9.4.e003111.8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216655"},{"key":"2025090313044147000_9.4.e003111.9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212662"},{"key":"2025090313044147000_9.4.e003111.10","first-page":"S40","article-title":"The disease activity score (DAS) and the disease activity score using 28 joint counts (DAS28) in the management of rheumatoid arthritis","volume":"34","author":"van Riel","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"2025090313044147000_9.4.e003111.11","first-page":"S65","article-title":"The development of the disease activity score (DAS) and the disease activity score using 28 joint counts (DAS28)","volume":"32","author":"van Riel","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"2025090313044147000_9.4.e003111.12","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/acr.21649","article-title":"Rheumatoid arthritis disease activity measures: American college of rheumatology recommendations for use in clinical practice","volume":"64","author":"Anderson","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090313044147000_9.4.e003111.13","doi-asserted-by":"crossref","unstructured":"ten Klooster PM , de Graaf N , Vonkeman HE . Association between pain phenotype and disease activity in rheumatoid arthritis patients: a non-Interventional, longitudinal cohort study. Arthritis Res Ther 2019;21. doi:10.1186\/s13075-019-2042-4","DOI":"10.1186\/s13075-019-2042-4"},{"key":"2025090313044147000_9.4.e003111.14","unstructured":"Swedish Rheumatology Quality Register . Annual reports [Internet]. Stockholm (SE): Swedish Association for Rheumatology; [Updated 2021; cited 2022 Nov 27], 2021. Available: https:\/\/srq.nu\/en\/annual-reports-health-professional\/"},{"key":"2025090313044147000_9.4.e003111.15","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310302"},{"key":"2025090313044147000_9.4.e003111.16","doi-asserted-by":"publisher","DOI":"10.3109\/03009748809098795"},{"key":"2025090313044147000_9.4.e003111.17","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg072"},{"key":"2025090313044147000_9.4.e003111.18","doi-asserted-by":"publisher","DOI":"10.1002\/art.30129"},{"key":"2025090313044147000_9.4.e003111.19","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/rheumatology\/key433","article-title":"Comparative effectiveness of Abatacept, Rituximab, Tocilizumab and TNFi Biologics in RA: results from the nationwide Swedish register","volume":"58","author":"Frisell","year":"2019","journal-title":"Rheumatology"},{"key":"2025090313044147000_9.4.e003111.20","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21747"},{"key":"2025090313044147000_9.4.e003111.21","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210283"},{"key":"2025090313044147000_9.4.e003111.22","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwh090"},{"key":"2025090313044147000_9.4.e003111.23","unstructured":"R Core Team . R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing, 2021."},{"key":"2025090313044147000_9.4.e003111.24","doi-asserted-by":"crossref","first-page":"101439","DOI":"10.1016\/j.berh.2019.101439","article-title":"Pain without inflammation in rheumatic diseases","volume":"33","author":"Lampa","year":"2019","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2025090313044147000_9.4.e003111.25","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000001384"},{"key":"2025090313044147000_9.4.e003111.26","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000002324"},{"key":"2025090313044147000_9.4.e003111.27","doi-asserted-by":"crossref","first-page":"105242","DOI":"10.1016\/j.jbspin.2021.105242","article-title":"High patient global assessment scores in patients with rheumatoid arthritis otherwise in remission do not reflect subclinical inflammation","volume":"88","author":"Brites","year":"2021","journal-title":"Joint Bone Spine"},{"key":"2025090313044147000_9.4.e003111.28","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/acr.23284","article-title":"Suppressing inflammation in rheumatoid arthritis: does patient global assessment blur the target? A practice-based call for a paradigm change","volume":"70","author":"Ferreira","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090313044147000_9.4.e003111.29","doi-asserted-by":"publisher","DOI":"10.1002\/art.33506"},{"key":"2025090313044147000_9.4.e003111.30","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.039859"},{"key":"2025090313044147000_9.4.e003111.31","doi-asserted-by":"crossref","DOI":"10.1186\/ar2270","article-title":"Remission by composite scores in rheumatoid arthritis: are ankles and feet important","volume":"9","author":"Kapral","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"2025090313044147000_9.4.e003111.32","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/acr2.11258","article-title":"Foot and ankle problems in patients with rheumatoid arthritis in 2019: still an important issue","volume":"3","author":"Simonsen","year":"2021","journal-title":"ACR Open Rheumatol"},{"key":"2025090313044147000_9.4.e003111.33","doi-asserted-by":"crossref","unstructured":"Nikiphorou E , Radner H , Chatzidionysiou K , et al . Patient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literature. Arthritis Res Ther 2016;18. doi:10.1186\/s13075-016-1151-6","DOI":"10.1186\/s13075-016-1151-6"},{"key":"2025090313044147000_9.4.e003111.34","doi-asserted-by":"publisher","DOI":"10.1002\/art.34543"},{"key":"2025090313044147000_9.4.e003111.35","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20685"},{"key":"2025090313044147000_9.4.e003111.36","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/acr.22953","article-title":"Direct and indirect determinants of the patient global assessment in rheumatoid arthritis: differences by level of disease activity","volume":"69","author":"Ward","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090313044147000_9.4.e003111.37","doi-asserted-by":"publisher","DOI":"10.1002\/art.38016"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2023-003111","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:04:49Z","timestamp":1756929889000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2023-003111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":37,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,11,16]]},"published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.1136\/rmdopen-2023-003111"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2023-003111","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11]]}}}